Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Shares Outstanding (Weighted Average): 2021-2025

Historic Shares Outstanding (Weighted Average) for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $28.9 million.

  • Krystal Biotech's Shares Outstanding (Weighted Average) rose 0.74% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 0.74%. This contributed to the annual value of $28.8 million for FY2024, which is 1.65% up from last year.
  • As of Q3 2025, Krystal Biotech's Shares Outstanding (Weighted Average) stood at $28.9 million, which was up 0.15% from $28.9 million recorded in Q2 2025.
  • Krystal Biotech's Shares Outstanding (Weighted Average)'s 5-year high stood at $28.9 million during Q3 2025, with a 5-year trough of $22.2 million in Q1 2021.
  • For the 3-year period, Krystal Biotech's Shares Outstanding (Weighted Average) averaged around $28.1 million, with its median value being $28.6 million (2024).
  • Data for Krystal Biotech's Shares Outstanding (Weighted Average) shows a peak YoY rose of 15.78% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Krystal Biotech's Shares Outstanding (Weighted Average) stood at $22.2 million in 2021, then increased by 15.78% to $25.7 million in 2022, then increased by 9.88% to $28.3 million in 2023, then rose by 1.65% to $28.8 million in 2024, then climbed by 0.74% to $28.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $28.9 million in Q3 2025, compared to $28.9 million in Q2 2025 and $28.8 million in Q1 2025.